A Single-Blinded Assessment of the Short-Term Effects of Cabergoline vs. Carbidopa/Levodopa on SPECT Dopamine Transporter Density in Out-Patient Subjects With Parkinson's Disease.

Trial Profile

A Single-Blinded Assessment of the Short-Term Effects of Cabergoline vs. Carbidopa/Levodopa on SPECT Dopamine Transporter Density in Out-Patient Subjects With Parkinson's Disease.

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Jun 2015

At a glance

  • Drugs Cabergoline; Levodopa/carbidopa
  • Indications Parkinson's disease
  • Focus Pharmacodynamics
  • Most Recent Events

    • 29 Jun 2011 New source identified and integrated (European Clinical Trials Database)
    • 01 Sep 2009 Planned number of patients changed from 120 to 30 as reported by ClinicalTrials.gov.
    • 16 Jan 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top